Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

This study has been completed.
Sponsor:
Information provided by:
Tottori University Hospital
ClinicalTrials.gov Identifier:
NCT00663195
First received: April 18, 2008
Last updated: NA
Last verified: April 2008
History: No changes posted
  Purpose

The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.


Condition Intervention Phase
Chronic Stable Heart Failure
Drug: spironolactone + furosemide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure

Resource links provided by NLM:


Further study details as provided by Tottori University Hospital:

Primary Outcome Measures:
  • MMP levels [ Time Frame: 16 weeks ]

Enrollment: 16
Study Start Date: January 2004
Study Completion Date: December 2005
Intervention Details:
    Drug: spironolactone + furosemide
    spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
Detailed Description:

Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • chronic stable heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Kazuhide Ogino, Center for Clinical Residency Program, Tottori University Hospital
ClinicalTrials.gov Identifier: NCT00663195     History of Changes
Other Study ID Numbers: #344
Study First Received: April 18, 2008
Last Updated: April 18, 2008
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Tottori University Hospital:
heart failure
fibrosis
MMP
spironolactone
furosemide

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Furosemide
Spironolactone
Cardiovascular Agents
Diuretics
Diuretics, Potassium Sparing
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Membrane Transport Modulators
Mineralocorticoid Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014